Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab

Background: It is unclear whether multiple sclerosis (MS) patients receiving ofatumumab mount an immune response after SARS-CoV-2 mRNA vaccination. Methods: KYRIOS is an ongoing, multicenter, open-label, prospective clinical study on immune responses in MS patients after initial or booster SARS-CoV-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Groth, Marie, Ettle, Benjamin, Bopp, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782480/
https://www.ncbi.nlm.nih.gov/pubmed/36560576
http://dx.doi.org/10.3390/vaccines10122167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782480/
https://www.ncbi.nlm.nih.gov/pubmed/36560576
http://dx.doi.org/10.3390/vaccines10122167

Ejemplares similares